Genentech Reports P-III (BALATON) and (COMINO) Studies Results of Vabysmo (faricimab-svoa) for the Treatment of Retinal Vein Occlusion
Shots:
- The P-III (BALATON) study in 553 patients with branch retinal vein occlusion and (COMINO) study in 729 patients with central retinal or hemiretinal vein occlusion evaluating Vabysmo vs aflibercept in a ratio (1:1)
- The trials met its 1EPs i.e., patients treated with Vabysmo (q4w) for ~24wks. achieved non-inferior visual acuity gains over aflibercept, rapid drying of retinal fluid from baseline through 24wk. as measured by reduction in CST, was well tolerated & the safety profile was consistent with prior trials
- The results will be presented at an upcoming medical meeting and submitted to regulatory authorities globally. Vabysmo has been approved in +40 countries globally incl. the US, Japan, the UK, and the EU for wet, or neovascular AMD & DME
Ref: Businesswire | Image: Genentech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
